MedPath

Klisyri

These highlights do not include all the information needed to use KLISYRI safely and effectively. See full prescribing information for KLISYRI. KLISYRI (tirbanibulin) ointment, for topical use Initial U.S. Approval: 2020

Approved
Approval ID

589c8de8-b773-4d47-b60c-48471806cccc

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 21, 2023

Manufacturers
FDA

Almirall, LLC

DUNS: 605425912

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

tirbanibulin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code16110-391
Application NumberNDA213189
Product Classification
M
Marketing Category
C73594
G
Generic Name
tirbanibulin
Product Specifications
Route of AdministrationTOPICAL
Effective DateDecember 18, 2020
FDA Product Classification

INGREDIENTS (3)

TIRBANIBULINActive
Quantity: 10 mg in 1 g
Code: 4V9848RS5G
Classification: ACTIB
GLYCERYL MONO AND DIPALMITOSTEARATEInactive
Code: KC98RO82HJ
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Klisyri - FDA Drug Approval Details